Black Diamond Therapeutics Inc logo

BDTX - Black Diamond Therapeutics Inc News Story

$26.56 -1.3  -4.6%

Last Trade - 13/05/21

Sector
Healthcare
Size
Mid Cap
Market Cap £716.7m
Enterprise Value £492.5m
Revenue £n/a
Position in Universe 2809th / 6855

Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021

Tue 2nd March, 2021 9:05pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210302:nGNX4H7T1L&default-theme=true


CAMBRIDGE, Mass. and NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Black
Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine
company pioneering the discovery and development of small molecule,
tumor-agnostic therapies, today announced the presentation of pre-clinical
data from two programs emerging from the Company’s proprietary MAP platform
targeting BRAF and fibroblast growth factor receptor (FGFR) at the European
Society of Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual
Congress 2021, taking place March 1-2, 2021.

“BRAF and FGFR are validated oncogenes, yet current standards of care have
meaningful limitations giving rise to substantial unmet need for cancer
patients,” said Chris Roberts, Ph.D., Chief Scientific Officer of Black
Diamond Therapeutics. “In contrast, our BRAF and FGFR program compounds are
designed to be potent MasterKey inhibitors of spectrums of previously
uncharacterized allosteric oncogenic driver mutations that were identified and
validated by our proprietary MAP platform.”

Dr. Roberts continued, “Our programs aim to address specific deficiencies
associated with current-generation therapies. Our BRAF program compounds are
designed to target the full spectrum of BRAF oncogenic mutations and avoid
paradoxical activation, which leads to secondary malignancies. Our FGFR
compounds are designed to target the full spectrum of oncogenic FGFR2 and
FGFR3 mutations while sparing FGFR1 and retaining activity against gatekeeper
mutations, supporting the potential capture of efficacy otherwise left on the
table. Collectively, these pre-clinical data support the potential of both
programs to generate differentiated product candidates for patients.”

The presentations describe the following data:

BRAF Program:
The presentation describes pre-clinical data for Black Diamond’s BRAF
program candidates, which are designed for potency against a spectrum of
non-canonical Class II/III (non-V600) mutations, as well as to avoid induction
of paradoxical activation.
* BRAF program candidates potently inhibit the proliferation of Ba/F3
transformants expressing a broad spectrum of non-canonical, dimer-promoting
Class II/III mutations.
* Current-generation BRAF therapies often induce paradoxical activation that
can lead to secondary malignancies. In contrast, treatment of cells harboring
WT-BRAF with Black Diamond’s BRAF program candidates was not observed to
lead to an increase in pERK, a signal of paradoxical activation, in
pre-clinical studies.
* BRAF program candidates demonstrate anti-tumor activity in mutant BRAF
dimer-driven allograft models (Ba/F3-expressing BRAF-KIAA1549 or BRAF-G469A)
and BRAF V600E-driven patient-derived xenograft (PDX) models (A375).
* An Investigational New Drug (IND) is anticipated in 2022.
FGFR Program:
The presentation illustrates the Black Diamond approach, which centers on a
four-pronged optimization strategy designed to deliver an inhibitor with broad
coverage of FGFR2 and FGFR3 oncogenes, while sparing inhibition of FGFR1 and
retaining activity against gatekeeper mutations.
* Inhibition of FGFR1 is associated with a toxicity profile that causes dose
reductions/interruptions, which limits the efficacy of current-generation
therapies. In endogenous FGFR cell lines, the FGFR program compounds
demonstrate potent activity against a spectrum of FGFR2/3 mutations while
sparing FGFR1.
* FGFR program compounds demonstrate potent activity against gatekeeper
mutations in FGFR2/3 in isogenic cell lines, supporting the potential for a
higher barrier against drug-resistant mutations.
* FGFR program compounds, when dosed at well-tolerated doses, demonstrated
tumor regression in the UMUC14 bladder model expressing the FGFR3-S249C
mutation in a PDX mouse model.
* An IND is anticipated in 2022.
“Our BRAF and FGFR programs are two exemplars of our MasterKey approach to
drug development in which we have leveraged our proprietary MAP platform to
identify and validate previously uncharacterized oncogenic driver mutations,
aggregate them into families, and design candidates to target the entire
family of mutations,” said David M. Epstein, Ph.D., President and Chief
Executive Officer of Black Diamond Therapeutics. “These programs demonstrate
how our MAP Platform continues to deliver product candidates that we believe
can address areas of unmet need.”

The presentations from the ESMO TAT meeting are available on the “Scientific
Presentations and Publications” section of the Black Diamond Therapeutics
website.

About Black Diamond

Black Diamond Therapeutics is a precision oncology medicine company pioneering
the discovery of small molecule, tumor-agnostic therapies. Black Diamond
targets undrugged mutations in patients with genetically defined cancers.
Black Diamond is built upon a deep understanding of cancer genetics, protein
structure and function, and medicinal chemistry. The Company’s proprietary
technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is
designed to allow Black Diamond to analyze population-level genetic sequencing
data to identify oncogenic mutations that promote cancer across tumor types,
group these mutations into families, and develop a single small molecule
therapy in a tumor-agnostic manner that targets a specific family of
mutations. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth
Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began
building the MAP platform and chemistry discovery engine. For more
information, please visit www.blackdiamondtherapeutics.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding the continued
development of the BRAF and FGFR programs, including timing of potential IND
filings in the programs. Any forward-looking statements in this statement are
based on management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by such
forward-looking statements. Risks that contribute to the uncertain nature of
the forward-looking statements include: the success, cost, and timing of the
Company’s product candidate development activities and planned IND-enabling
and clinical trials, the Company’s ability to execute on its strategy,
regulatory developments in the United States, the Company’s ability to fund
operations, and the impact that the current COVID-19 pandemic will have on the
Company’s pre-clinical studies and clinical trials, supply chain, and
operations, as well as those risks and uncertainties set forth in its 2019
annual report on Form 10-K filed with the United States Securities and
Exchange Commission and its other filings filed with the United States
Securities and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were made. The
Company undertakes no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they were made.

Contacts:

For Investors:
Natalie Wildenradt
investors@bdtx.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com


(https://www.globenewswire.com/NewsRoom/AttachmentNg/b8da4d92-789b-4f0a-a1e2-2739af370155)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.